- CEO
- Chun Lung Chiu
- Full Time Employees
- 128
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- No. 80, Kangning Street New Taipei TP Taiwan 221
- IPO Date
- Sep 10, 2004
- Business
- Level Biotechnology Inc. engages primarily in the marketing and distribution of biomedical products and the provision of preclinical contract research organization (CRO) services. Its main product portfolio includes cell culture products; immunology reagents; molecular biology products; biomedical precision instruments and equipment; and laboratory consumables and reagents. The company operates preclinical testing services covering mammalian toxicology, genetic toxicology, pharmacology, biocompatibility, and model animal production. These offerings target biotech, pharmaceutical, medical device, animal health, and agrichemical industries. Founded in 1989 and headquartered in New Taipei City, Taiwan, Level Biotechnology has established a reputed presence in Taiwan and maintains partnerships with international suppliers such as Corning Life Science, Biochrom AG, Millipore-Chemicon, and others.
In recent years, Level Biotechnology has expanded its CRO services significantly, focusing on preclinical services for new chemical entities (NCE), biopharmaceutics, and medical devices, enhancing its service quality certified under ISO9001:2000. The company reported ongoing revenue growth and improved net income performance through 2025, reflecting operational enhancements and market expansion. Level Biotechnology emphasizes a one-stop-shop model for preclinical research, streamlining regulatory toxicology, customized study designs, and disease models for clients globally. There have been no major announced mergers or acquisitions, but the company continues to bolster its service portfolio and operational capabilities to support evolving biomedical research and development needs in its markets.
Level Biotechnology operates extensively within Taiwan and internationally through its CRO services, providing comprehensive biomedical research support alongside its distribution business. The firm’s integration of product distribution with specialized preclinical services positions it as a significant player in biotechnology research, development, and supply chains in the Asia-Pacific region. The company’s strategic focus remains on expanding service depth and fostering strong client relationships across biomedical sectors while maintaining competitive product offerings sourced from leading global brands. This combined approach enables Level Biotechnology to address diversified market demands in biomedical science and technology development.